[{"uuid": "3974e9de-810c-3665-931e-c325a6593fc5", "title": "Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and\u00a0Key Differentiators in its CLS-AX Clinical Program", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/clearside-biomedical-announces-multiple-medical-120500726.html", "providerPublishTime": 1738065900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/e11I8E0T6nmoz7Jja7Ow7w--~B/aD02NTI7dz0yMTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2c6c125b19684876f24b4e7ecaae6a1a", "width": 2100, "height": 652, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/0LIduNJ2k7lv.mU7Z897_A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2c6c125b19684876f24b4e7ecaae6a1a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLSD"]}, {"uuid": "40471be0-dbaa-3c7b-8eaf-a9cdff6a7fc2", "title": "Clearside's Partner Receives NDA Approvals for Uveitic Macular Edema Treatment in Australia, Singapore", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/clearside-apos-partner-receives-nda-165207589.html", "providerPublishTime": 1737564727, "type": "STORY", "relatedTickers": ["CLSD"]}, {"uuid": "a121c009-bc1c-3180-9eb2-8f19c46cf95e", "title": "Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/clearside-biomedical-announces-asia-pacific-120500581.html", "providerPublishTime": 1737547500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/e11I8E0T6nmoz7Jja7Ow7w--~B/aD02NTI7dz0yMTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2c6c125b19684876f24b4e7ecaae6a1a", "width": 2100, "height": 652, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/0LIduNJ2k7lv.mU7Z897_A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2c6c125b19684876f24b4e7ecaae6a1a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLSD"]}, {"uuid": "0ddbccf3-3837-3f1d-a66d-e708f705ea07", "title": "Sector Update: Health Care Stocks Softer Late Afternoon", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-205205529.html", "providerPublishTime": 1737579125, "type": "STORY", "relatedTickers": ["ABT", "CLSD"]}, {"uuid": "9514735b-fc92-3b2a-a6a6-cb37a760a2fb", "title": "Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/heres-why-clearside-biomedical-clsd-145505587.html", "providerPublishTime": 1734015305, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/d6hN0_BhikrNdWTnix6fng--~B/aD03NDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2", "width": 900, "height": 741, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/fK_ZnUjpgS53xdJHns_S2A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLSD"]}, {"uuid": "a360f0a4-957c-30de-8894-7d8a2ae784d7", "title": "Clearside announces publication of insights on drug development, regulation", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/clearside-announces-publication-insights-drug-121619328.html", "providerPublishTime": 1734696979, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/qPv1d3QqkuUgAPFZhs.xQg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/77a747ee2b92f942aa044f4f47d9af54", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/nmFLXrYVJ_1CdQ08mbrXvA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/77a747ee2b92f942aa044f4f47d9af54", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLSD"]}, {"uuid": "fbb31d7e-6c02-35e9-a451-eb977f529809", "title": "Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/clearside-biomedical-inc-clsd-reports-230520816.html", "providerPublishTime": 1731452720, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ksLAzii1aL14haHFbPC1Rg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f", "width": 900, "height": 601, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/sz.PXkOG_KtvLQskImJYTA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLSD"]}, {"uuid": "7cb452ff-3ac2-33b5-81b0-1dc10824e378", "title": "Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/clearside-biomedical-announces-publication-critical-120500683.html", "providerPublishTime": 1734609900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/e11I8E0T6nmoz7Jja7Ow7w--~B/aD02NTI7dz0yMTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2c6c125b19684876f24b4e7ecaae6a1a", "width": 2100, "height": 652, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/0LIduNJ2k7lv.mU7Z897_A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2c6c125b19684876f24b4e7ecaae6a1a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLSD"]}, {"uuid": "a7993d91-bef2-3e1f-9d41-903d19ba067c", "title": "All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/know-clearside-biomedical-clsd-rating-170011179.html", "providerPublishTime": 1731690011, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1", "width": 900, "height": 602, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/HGBb_w3iAqceoCyVMucmoA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLSD"]}, {"uuid": "34105a04-fe15-3eba-843d-c887c148a9f9", "title": "Analyst Sees 500% Upside for This Pharmaceutical  Penny Stock", "publisher": "GuruFocus.com", "link": "https://finance.yahoo.com/news/analyst-sees-500-upside-pharmaceutical-102938205.html", "providerPublishTime": 1734690578, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Q0kOm_8VIyLyexjr65V05Q--~B/aD0yODI7dz00MjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/470ebe3d1efe6844779cf2275a9060c3", "width": 425, "height": 282, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/.OVkBKjaJGTEeLXSQrgEBA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/470ebe3d1efe6844779cf2275a9060c3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLSD"]}, {"uuid": "184cf689-b50b-338b-91ba-9988f8e2ee74", "title": "Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ...", "publisher": "GuruFocus.com", "link": "https://finance.yahoo.com/news/clearside-biomedical-inc-clsd-q3-071721822.html", "providerPublishTime": 1731482241, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/sOoMEm_U06y1kXa37Ot4Vg--~B/aD0yNTY7dz0yNTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/ef4296749bacf2144204c8c9d3aada76", "width": 256, "height": 256, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/lKQPIpgGgH12u3IE.QPRcQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/ef4296749bacf2144204c8c9d3aada76", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLSD"]}, {"uuid": "692b79e6-7431-31f6-ad2b-87aaf5766c3c", "title": "Even after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three years", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/even-rising-13-past-week-124001830.html", "providerPublishTime": 1731242401, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/hG0OCZI55yVVgXDa9Dxy1Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CLSD"]}]